188 related articles for article (PubMed ID: 19754361)
1. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
2. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
3. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
4. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
5. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin.
Baker JH; Kyle AH; Bartels KL; Methot SP; Flanagan EJ; Balbirnie A; Cran JD; Minchinton AI
PLoS One; 2013; 8(10):e76832. PubMed ID: 24204680
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
10. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells.
Masunaga SI; Ono K; Suzuki M; Kinashi Y; Takagaki M; Hori H; Kasai S; Nagasawa H; Uto Y
Jpn J Cancer Res; 2000 May; 91(5):566-72. PubMed ID: 10835503
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
[TBL] [Abstract][Full Text] [Related]
13. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):396-9. PubMed ID: 21205223
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
16. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
17. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
18. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
[TBL] [Abstract][Full Text] [Related]
19. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.
Chen CS; Jounaidi Y; Su T; Waxman DJ
Cancer Gene Ther; 2007 Dec; 14(12):935-44. PubMed ID: 17853921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
